Compare Amgen, Inc. (AMGN) vs PulteGroup, Inc. (PHM) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Amgen, Inc. vs PulteGroup, Inc. — how do they compare? Amgen, Inc. trades at $363.66 (market cap $196.12B), while PulteGroup, Inc. trades at $124.58 (market cap $23.76B). The key difference: Amgen, Inc. is far larger — about 8.3× PulteGroup, Inc.'s market cap, and Amgen, Inc. pays the higher dividend (2.77%). Which is the better fit depends on your goals.
| AMGN | PHM | |
|---|---|---|
Market Cap | $196.12B | $23.76B |
Sector | Health | Consumer Cyclical |
52-Week High | $388.16 | $142.56 |
52-Week Low | $271.18 | $108.00 |
Enterprise Value | $241.41B | $23.72B |
Dividend Yield | 2.77% | 0.83% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMGN trades at $363.39, down slightly by 0.06% today, with a bullish technical signal from moving averages. The company reported strong Q1 2026 earnings, beating estimates with EPS of $5.15 versus $4.77 expected. Revenue grew to $36.75B in 2025, with a net income margin of 20.96%. Recent news includes a favorable court ruling blocking a price cap on Enbrel in Colorado, but regulatory challenges persist for Tavneos in Europe.
The outlook remains positive due to consistent earnings beats and a diversified product portfolio, though risks include regulatory setbacks and competitive pressures. Analyst consensus is bullish with a 57.9% buy rating and a price target of $357.38, slightly below the current price, indicating potential for stability with upside from pipeline developments.
PulteGroup (PHM) trades at $124.75, up 0.83% on the day, with a bearish technical signal despite recent price strength. The stock shows mixed earnings performance with Q3 2025 beating estimates but subsequent quarters missing, while maintaining solid profitability with a 12.14% net margin. Recent news highlights new community developments and sector attention, though technical indicators suggest caution with RSI at neutral levels and key resistance at $125.
The outlook for PHM is balanced; analyst consensus targets $150.60 (21% upside) with 45% buy ratings, but near-term risks include margin pressure and housing market volatility. Earnings growth remains the key catalyst for sustained upside, while macroeconomic factors pose headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amgen, Inc.
Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).
Read more on AMGN →About PulteGroup, Inc.
PulteGroup Inc is one of the largest homebuilders in the United States, operating in 40 markets across 23 states. The company mainly builds single-family detached homes (85% of unit sales) and offers products to entry-level, move-up, and active-adult buyers. PulteGroup offers homebuyers mortgage financing and title agency services through its financial services segment. The company is headquartered in Atlanta.
Read more on PHM →
